Aurobindo Pharma Stock Screener | Share Price & Fundamental Analysis
AUROPHARMA
Pharmaceuticals
Screen Aurobindo Pharma share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹1235.40
▲
4.10 (0.33%)
Share Price BSE
₹1235.30
▲
3.60 (0.29%)
Market Cap
₹71,752.23 Cr.
P/E Ratio (TTM)
20.91
P/B Ratio
2.04
EPS (TTM)
₹59.81
Dividend Yield
-
Debt to Equity
0.24
52W High
₹1257.80
52W Low
₹1025.00
Operating Margin
21.00%
Profit Margin
10.60%
Revenue (TTM)
₹8,516.00
EBITDA
₹1,894.00
Net Income
₹903.00
Total Assets
₹49,785.00
Total Equity
₹32,647.00
Aurobindo Pharma Share Price History - Stock Screener Chart
Screen AUROPHARMA historical share price movements with interactive charts. Analyze price trends and patterns.
Aurobindo Pharma Company Profile - Fundamental Screener
Screen Aurobindo Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for AUROPHARMA shares.
Aurobindo Pharma Limited (APL) is an Indian pharmaceutical company founded in 1986. It manufactures and markets active pharmaceutical ingredients, generic formulations, and branded pharmaceuticals globally. APL specializes in various therapeutic areas including antibiotics, antiretrovirals, cardiovascular, central nervous system, and gastroenterological products. The company operates 24 manufacturing plants worldwide and has...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
M R Kumar
ISIN
INE406A01037
Website
https://www.aurobindo.com
Aurobindo Pharma Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen AUROPHARMA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 49,785 | 45,072 | 39,890 | 33,922 | 33,854 | 28,928 | 26,454 | 21,101 | 16,249 | 15,920 |
| Current Assets | 27,163 | 23,772 | 21,460 | 18,123 | 19,824 | 16,413 | 15,332 | 12,178 | 9,206 | 10,294 |
| Fixed Assets | 14,794 | 14,493 | 11,024 | 10,532 | 9,374 | 9,397 | 8,475 | 6,521 | 4,834 | 4,180 |
| Liabilities | ||||||||||
| Total Liabilities | 49,785 | 45,072 | 39,890 | 33,922 | 33,854 | 28,928 | 26,454 | 21,101 | 16,249 | 15,920 |
| Current Liabilities | 2,456 | 3,022 | 1,544 | 1,192 | 1,260 | 718 | 541 | 753 | 270 | 790 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 32,647 | 29,851 | 26,852 | 24,574 | 21,929 | 16,825 | 13,892 | 11,682 | 9,374 | 7,290 |
| Share Capital | 58 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 |
| Reserves & Surplus | 32,595 | 29,784 | 26,781 | 24,517 | 21,871 | 16,766 | 13,832 | 11,622 | 9,313 | 7,229 |
Screen AUROPHARMA income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8,516 | 7,899 | 8,359 | 7,628 | 7,679 | 7,783 | 8,052 | 6,514 | 6,907 | 7,339 | 7,434 | 5,844 | 6,218 | 5,731 | 6,481 |
| Expenses | 6,622 | 6,265 | 6,608 | 6,042 | 5,949 | 6,230 | 6,401 | 5,477 | 5,772 | 5,846 | 5,753 | 5,002 | 5,303 | 4,950 | 5,453 |
| EBITDA | 1,894 | 1,634 | 1,752 | 1,585 | 1,730 | 1,553 | 1,652 | 1,037 | 1,135 | 1,493 | 1,681 | 842 | 914 | 781 | 1,027 |
| Operating Profit % | 21.00% | 20.00% | 20.00% | 19.00% | 20.00% | 19.00% | 19.00% | 14.00% | 15.00% | 18.00% | 21.00% | 14.00% | 14.00% | 13.00% | 15.00% |
| Depreciation | 444 | 406 | 429 | 354 | 404 | 382 | 419 | 346 | 327 | 418 | 423 | 254 | 280 | 298 | 321 |
| Interest | 115 | 98 | 95 | 89 | 111 | 113 | 119 | 56 | 57 | 68 | 76 | 9 | 15 | 25 | 45 |
| Profit Before Tax | 1,335 | 1,207 | 1,276 | 1,230 | 1,324 | 1,208 | 1,200 | 730 | 812 | 1,076 | 1,262 | 594 | 679 | 523 | 680 |
| Tax | 432 | 383 | 428 | 323 | 406 | 391 | 354 | 224 | 242 | 324 | 323 | 18 | 159 | 113 | 189 |
| Net Profit | 903 | 824 | 848 | 907 | 918 | 817 | 846 | 506 | 570 | 752 | 940 | 576 | 520 | 410 | 491 |
| EPS | 15.56 | 14.20 | 14.61 | 15.51 | 15.69 | 14.00 | 14.56 | 8.64 | 9.74 | 12.83 | 16.04 | 9.84 | 8.88 | 6.99 | 8.38 |
Aurobindo Pharma Cash Flow Screener - Liquidity Fundamentals
Screen AUROPHARMA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 3,925 | 2,435 | 2,387 | 5,017 | 3,329 | 4,381 | 1,651 | 1,955 | 3,279 | 1,420 |
| Investing Activities | -1,866 | -4,242 | -3,971 | -3,211 | 597 | -1,563 | -2,904 | -1,927 | -1,787 | -1,446 |
| Financing Activities | 120 | 800 | 1,814 | -2,969 | -1,365 | -1,947 | 1,919 | 864 | -1,915 | 365 |
| Net Cash Flow | 2,178 | -1,007 | 230 | -1,164 | 2,561 | 871 | 666 | 892 | -424 | 340 |
Screen AUROPHARMA shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 51.82% | 51.82% | 51.82% | 51.83% | 51.80% | 51.82% | 51.82% | 51.83% |
| FII Holding | 15.33% | 14.37% | 14.21% | 18.02% | 16.73% | 16.59% | 16.29% | 0.00% |
| DII Holding | 26.23% | 26.93% | 27.60% | 23.28% | 24.77% | 25.13% | 25.20% | 15.08% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 5.47% | 5.67% | 5.25% | 5.52% | 5.47% | 5.33% | 5.52% | 8.54% |
| Other Holding | 1.15% | 1.20% | 1.13% | 1.36% | 1.23% | 1.13% | 1.17% | 24.54% |
| Shareholder Count | 269,323 | 272,208 | 247,662 | 244,575 | 238,622 | 248,488 | 257,962 | 343,617 |
Aurobindo Pharma Dividend Screener - Share Yield Analysis
Screen AUROPHARMA dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹4.50 | 0.39% |
| 2023-March | ₹7.50 | 0.69% |
| 2022-March | ₹9.00 | 1.77% |
| 2021-March | ₹4.00 | 0.60% |
| 2020-March | ₹3.00 | 0.34% |
| 2019-March | ₹2.50 | 0.61% |
| 2018-March | ₹2.50 | 0.32% |
| 2017-March | ₹3.20 | 0.57% |
Aurobindo Pharma Index Membership - Market Screener Classification
Screen AUROPHARMA by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Aurobindo Pharma Market Events Screener - Corporate Actions
Screen AUROPHARMA market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -0.84% | ||
| 2025-11-05 | 2025-11-05 | Quarterly Result Announcement | NA | 4.74% |
| 2025-08-08 | 2025-08-08 | Dividend | ₹ 4.00 /share | -0.94% |
| 2025-08-04 | 2025-08-04 | Quarterly Result Announcement | NA | -1.96% |
| 2025-05-26 | 2025-05-26 | Quarterly Result Announcement | NA | -1.63% |
| 2025-02-06 | 2025-02-06 | Quarterly Result Announcement | NA | 3.04% |
| 2024-11-09 | 2024-11-09 | Quarterly Result Announcement | NA | -4.90% |
| 2024-08-29 | 2024-08-29 | Annual General Meeting | NA | 11.38% |
| 2024-07-30 | 2024-08-05 | Buyback | 1460 | -2.41% |
| 2024-02-20 | 2024-02-20 | Dividend | ₹ 1.50 /share | 3.84% |
| 2023-11-20 | 2023-11-20 | Dividend | ₹ 3.00 /share | 7.58% |
| 2023-02-17 | 2023-02-17 | Dividend | ₹ 3.00 /share | 7.83% |
| 2022-06-06 | 2022-06-07 | Dividend | ₹ 4.50 /share | -1.36% |
| 2022-02-18 | 2022-02-21 | Dividend | ₹ 1.50 /share | 1.04% |
| 2021-11-17 | 2021-11-18 | Dividend | ₹ 1.50 /share | -3.41% |
Aurobindo Pharma Competitors Screener - Peer Comparison
Screen AUROPHARMA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 427,705 | 40.28 | 54,729 | 9.71% | 10,980 | 58.99 |
| Divis Laboratories | 176,338 | 70.98 | 9,712 | 18.67% | 2,191 | 63.15 |
| Torrent Pharmaceuticals | 138,499 | 62.26 | 11,539 | 6.99% | 1,911 | 80.95 |
| Cipla | 118,573 | 22.75 | 28,410 | 7.12% | 5,291 | 38.52 |
| Dr Reddys Laboratories | 103,728 | 18.27 | 33,741 | 16.73% | 5,725 | 40.17 |
| Lupin | 101,149 | 22.61 | 22,910 | 13.74% | 3,306 | 71.67 |
| Mankind Pharma | 95,432 | 52.17 | 12,744 | 20.90% | 2,007 | 64.16 |
| Zydus Life Science | 93,333 | 18.63 | 23,511 | 18.55% | 4,615 | 52.14 |
| Aurobindo Pharma | 71,752 | 20.91 | 32,346 | 9.43% | 3,484 | 61.25 |
| Alkem Laboratories | 69,425 | 28.04 | 13,458 | 3.70% | 2,216 | 63.97 |
Aurobindo Pharma Company Announcements - News Screener
Screen AUROPHARMA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-06 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2026-01-02 | Announcement under Regulation 30 (LODR)-Acquisition | View |
| 2025-12-31 | Announcement under Regulation 30 (LODR)-Updates on Acquisition | View |
| 2025-12-27 | Curateq Biologics Private Limited A Wholly Owned Subsidiary Of The Company Has Mutually Agreed To Terminate Its Agreement With Biofactura Inc USA | View |
| 2025-12-24 | Closure of Trading Window | View |
| 2025-12-23 | Announcement under Regulation 30 (LODR)-Acquisition | View |
| 2025-12-18 | Completion Of US FDA Inspection At Unit-IV Of APL Healthcare Limited A Wholly Owned Subsidiary Of The Company | View |
| 2025-12-15 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-12-12 | Completion Of US FDA Inspection At Unit-V Of Apitoria Pharma Private Limited A Wholly Owned Subsidiary Of The Company | View |
| 2025-12-02 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-27 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-14 | Completion Of US FDA Inspection At Unit II Of Eugia Pharma Specialities Ltd. Bhiwadi A Wholly Owned Subsidiary Of The Company | View |
| 2025-11-14 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-14 | Classification Of US FDA Inspection At Unit-I Of Apitoria Pharma Private Limited A Wholly Owned Subsidiary Of The Company As Voluntary Action Indicated (VAI) | View |
| 2025-11-11 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-05 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-05 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2025-11-05 | Board Meeting Outcome for Outcome Of The Board Meeting Held On November 5 2025 | View |
| 2025-11-04 | Announcement under Regulation 30 (LODR)-Change in Management | View |